Navigation Links
PreMD Inc. Completes Debenture Financing
Date:3/12/2008

ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new
'/>"/>

SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. PreMD Inc. Signs Agreement with Cosmetics Conglomerate
2. PreMD Inc. Announces Debenture Financing
3. PreMD Initiates FDA Review Process and Provides Corporate Update
4. PreMD Announces FDA Decision on POC Skin Cholesterol Test
5. PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
6. PreMD Inc. Provides Corporate Update
7. PreMD Provides Update on 510(k) Application for PREVU(x) POC
8. Gentiva(R) Health Services Completes Acquisition of Major Home Health Provider in CON State of Mississippi
9. Roche Completes Tender Offer for Ventana Shares
10. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
11. KV Pharmaceutical Company Completes Unaudited Fiscal 2007 Results; Receives Trading Extension From NYSE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... Kids, parents and schools need to work together t... FRIDAY, Nov. 21 (HealthDay News) -- Behavior that...cognized as bullying. , And as mounting researc... the victim, mental-health professionals, schools,...th new ways to combat this threatening behavior. ...
(Date:11/21/2008)..., HOUSTON(Nov. 21, 2008)The University of Texas He...rogram, Training Excellence in Aging Studies (TEXA...through a prestigious $2 million award from the Do...atching funds., "This will allow us to teach geri...t junior medical student to practicing physicians....
(Date:11/21/2008)... TUCSON, Ariz., Nov. 21 ...C ) today announced that Craig A. Norris, the Comp... to the Company,s Board of,Directors. Mr. Norris...2008,resignation of Steven I. Geringer and return...serve on any committee of the Board. , Mr. ...
(Date:11/21/2008)... Trials showed Banzel proved effective against Len... (HealthDay News) -- A new drug called Banzel (ruf...tment for a severe form of epilepsy called Lennox-...ation announced Friday. , The approval was base...ncluded patients ages 4 to 30. Compared to patient...
Breaking Medicine News(10 mins):Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 2Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 3Health News:UT Houston launches geriatric training with $3.25 million in grant, matching funds 4Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 2Health News:Craig A. Norris Appointed to Providence Service Corporation Board of Directors 3Health News:FDA Approves New Drug for Severe Epilepsy 2
...t the Shanghai Children’s Medical Center have succ...rare, well-developed third arm from a two-month-ol...t arms that had been laid across Liu Junjie's ches...is further up his shoulder. ‘We found the nerves ...
... Health Organisation has ruled out human-to-human ...esian nurses tending patients with the disease // ...he ability to spread more readily among humans. 'T...nurses provide reassuring evidence that the virus ...
... drug used to treat chronic myeloid leukemia has s...f patients with the cancer.// The National Institu...h regulates drug approvals in the UK had only want...s, but the drug has not proved itself in clinical ...
...ight is back on drugs and high life in Mumbai with...hospital, and Sahil Zarru, who is suspected to hav...arty circuit here. "Cocaine, ecstasy, acid and her...rugs,are a rage with the rich and the famous in Mu...
Other Medicine News:Health News:Drugs Part of Mumbai High Life 2
(Date:11/20/2008)... Calif., Nov. 20 Milk. It does a b...originally thought. After years of,research, scie...es found in,cow,s milk that stimulate the body,s ...ew the Multimedia News Release, go to:, http://www... While developing new cancer therapies, the chie...
(Date:11/20/2008)...Nov. 20 Clinical data from a prosp...nnual Veith Symposium shows DVT,treatment with th...us,Vascular, Inc. (Santa Clara, CA) successfully ...t 20 minutes. , This technique, called isol...ood flow more quickly and safely than current cath...
(Date:11/19/2008)...AKS, Calif., Nov. 19 Amg...ncology Company, a subsidiary of,Takeda Pharmaceu... that,enrollment in the Phase 3 MONET1 trial eval...clitaxel and carboplatin for the first-line treatm...) has been temporarily suspended,following a plan...
(Date:11/19/2008)...l., Nov. 19 Isogen, a contract dev...le filling, today announced the first,phase launc... founded to,specifically address the process, fac...ith the $2 billion highly-niched, low-volume clini...rket segment. , Companies can invest over $...
Breaking Medicine Technology:Photos: Peptides Discovered to Alleviate Chemotherapy Side Effects 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Isogen Launches Major New Facility to Address Global Biopharma Demand 2New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 1New Program Website Targets Jewish Children Teens and Adults Suffering from the Impact of Childhood Maltreatment 20926 2Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 1Ferndale and Foamix Execute License Agreement for Development of Non Steroidal Foam for Atopic Dermatitis 5760 2Chronic Stomach Inflammation Boosts Cancer Risk 20924 1Chronic Stomach Inflammation Boosts Cancer Risk 20924 2Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 1Canine Cancer Web Exclusive for Dog Owners and Lovers Presented by Morris Animal Foundation Features Colorado State and Cornell University Veterina 20919 2
...ieves All Key Endpoints for Both Efficacy and Safe...rstCall/ --,Indevus Pharmaceuticals, Inc. today an...inetic trial for NEBIDO (testosterone,undecanoate)...nder,development for the treatment of male hypogon...ng Pharma AG, Germany. The data,from the recently ...
... is evaluating zonisamide SR as a novel component ... June 07, 2007 /PRNewswire-FirstCall/ -- Orexigen(...ny focused on the,treatment of central nervous sys...day announced results from a Phase I trial evaluat...rietary,sustained-release (SR) formulation of zon...
Other Medicine Technology:Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 2OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 3OREXIGEN Therapeutics Announces Sustained-Release Formulation of,Zonisamide Shows Improved Tolerability When Compared to Immediate,Release Formulation 4
BD Vacutainer® PST™ Tubes contain spray-coated lithium heparin and a gel for plasma separation. They are used for plasma determinations in chemistry.
BD Vacutainer® Specialty Tubes - Sedimentation Rate Determination (SRD)
Inquire
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients.
Medicine Products: